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WE investigated a possible association between
serum concentrations of tumour necrosis factor z
(TNF-e0, interleukin-6 (IL-6) and their soluble
receptors (sTNF-et-Rp55 and sIL-6R) using an en-
zyme-linked immunosorbent assay (ELISA) in 55
patients with systemic lupus erythematodes (SLE)
and 16 healthy controls. We also examined a
possible association between the serum levels of
these peptides and SLE activity, as well as TNF-
and IL-6 concentrations and the levels of their
soluble receptors. The median concentrations of
TNF-z, sTNF--Rp55 and IL-6 were significantly
higher in SLE patients than in normal individuals.
In contrast, there was no difference between the
serum level of sIL-6R in both groups. We found
positive correlations between the serum concen-
trations of TNF-z and IL-6 as well as their soluble
receptors and disease activity. There were also
correlations between TNF-z and sTNF--Rp55 as
well as IL-6 and sIL-6R serum levels in SLE pa-
tients but there were no such correlations in the
normal control group. In conclusion, an increase
in the serum levels of TNF-z, sTNF-z-Rp55 and IL-
6 may become useful markers for SLE activity.
Patients with SLE have sIL-6R serum concentra-
tion similar to that as in normal individuals.
However, it correlates with disease activity and
the level of IL-6.
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Introduction
Systemic lupus erythematodes (SLE) is a disor-
der of generalized autoimmunity with multi-
system organ involvement and autoantibodies
against nuclear, cytoplasmic and cell surface
antigens. The disease is characterized by
2 B cell
activation and autoantibody formation. 1’ How-
ever, increasing evidence indicates to a critical
role of T cells, particularly CD4+ cells, in
inducing B cell hyperactivity.
3 To explain the
mechanisms responsible for immune dysregula-
tion in SLE, cytokines have become the object
of intensive studies.
2-4
Cytokines are a group of polypeptides synthe-
sized by the host in response to different
injuries. They may affect different cell functions
and are involved in immunity and inflammatory
response. Among the many cytokines, interleu-
kin-1 (IL-1), interleukin-6 (IL-6), interferon-5,
(IFN-,) and tumour necrosis factor-or (TNF-c0
seem to play the most important role in the
pathogenesis of inflammatory and autoimmune
diseases.4-6
The intracellular signals for the response to
cytokines are provided by cell surface re-
ceptors.7’8 Cytokine receptors exist also in
soluble forms, apparently deriving from proteo-
lyric cleavage from the cell surface forms.9
Several preliminary studies show conflicting
data on the correlations between some inflam-
matory cytokines and their soluble receptors’
levels in the serum of patients with SLE and
disease activity. An initial report suggested that
TNF<z was not elevated in the serum of lupus
patients except during infection.10 Subse-
quently, elevated TNF-z levels in SLE patients
compared with controls
11 and its correlation
with disease activity was reported. Similarly,
there have been several reports suggesting that
the levels of IL-6 are elevated in active
lupus.13-15 However, other reports do not sup-
port these observations.
16
The biological role of soluble cytokine recep-
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tors is not fully elucidated. They may modify immunosuppressive agents. Fifty-one patients
ligand concentrations by serving as stabilizing were treated with steroids and two of them
binding proteins, may downregulate membrane with azatioprine for some time during the
receptor number as a mechanism of genesis, course of their disease, but 20 of them had not
and may specifically inhibit ligand-receptor asso- been treated for at least 4 weeks before the
ciation in the extracellular space.
16 investigation of cytokines.
Two receptors of different molecular struc- We included in the study patients with active
ture have been recognized for TNF<z: type I or and inactive disease. Disease activity was scored
TNF Rp55, of 55-60 kDa and type II or TNF- during the visit to the outpatient clinic accord-
Rp75, with 75-80 kDa molecular mass.7 Soluble ing to the method proposed by Liang et al. in
forms of these two TNF receptors (sTNF-Rs) our modification.26 Each patient was assessed
have been identified in serum and urine.9’17 on two separate occasions 2-4 weeks apart.
Neutrophils, activated T-cells and monocytes The system Systemic Lupus Activity Measure
are the main sources of sTNF<z-Rs)7 Their (SLAM) includes 24 clinical manifestations and
concentration in serum increases significantly in eight laboratory parameters.
inflammatory and cancer diseases.7’1 Both Parameters of immune function were not
types of sTNF-(zRs have been reported to be included. Maximal score points in this system is
elevated in patients with SLE.19-21 The sTNF- 84. We assumed the score of 0-10 points for
(-Rs levels correlate with disease activity and inactive disease, and a score of over 10 points
the impairment of renal function may contri- for active disease. Our group of patients in-
bute to a rise of their serum concentrations.19 eluded 13 inactive patients and 42 active
These sTNF-(z-Rs appear to be biologically func- disease patients (Table 1).
tional because they inhibited TNF-(z action in The control group of 15 healthy volunteers
cytotoxicity assays.21 was also studied. They were 14 women and one
The cellular IL-6R complex consists of two man, aged from 25 to 50 years (median 39
different proteins, an 80-kDa ligand binding years).
glycoprotein (IL-6R) and a 130-kDa protein (gp
130) involved in cellular signal transduction.22
Laboratory tests MOllberg et al. have recently shown that two
subunits of the IL-6R complex are proteolyti- On the day of blood sampling for TNF-, IL-6
cally cleaved and released from the cell as and their soluble receptors the following labora-
soluble receptor proteins.23’24 Their concentra- tory parameters were analysed: complete blood
tions seem to be elevated during infections, cell count (CBC), erythrocyte sedimentation
inflammatory and neoplastic diseases. In con- rate (ESR), blood urea nitrogen and creatinine
trast to other soluble cytokine receptors, the levels, fibrinogen level, partial thromboplastin
slL-6R together with IL-6 acts agonistically on
cells that express gp 130. To our best know-
ledge, the serum level of slL-6R in SLE patients Table 1. Clinical characteristics of patients with systemic
has not been investigated so far. lup27us erythematodes (symptoms according to Liang et
In the present study we measured the serum a/.
concentrations of TNF-(z, and IL-6 and their Symptom
soluble receptors (sTNF-(z-R55 and slL-6R) in 55
patients with SLE using ELISA assay. We also Total
correlated the serum levels of these proteins Active
with disease activity. Inactive
Fever
No. of (%)
patients
55 (100)
42 (76.4)
13 (23.6)
7 (12.7)
Skin symptoms 49
Reticuloendothelial system involvement 27
Patients and Methods Pulmonary symptoms
Cardiovascular symptoms
Patients Neurologic disorder
Arthritis
A total of 55 unselected patients with SLE, 53 Renal disorder (creatinine > 1.3mg/dl)
women and two men all fulfilling the 1982
Antinuclearantibodies
Anaemia (Hb < 12 g/dl)
revised criteria defined by the American Rheu- Leukopenia (< 3.5 x 109/I WBC)
rnatism Association (ARA)
25 were included in Thrombocytopenia (< 150 109/I
our study. Their mean age was 40 5 years (range
platelet)
Raised ESR (> 25 ram/h) 37
20-66 years). The mean duration of their Fibrinogen(>400mg/dl) 18
disease was 87.4 months (range 4 months to 30 Treatment with steroids during the 35
years). Four patients were never treated with study
(89.1)
(49.1)
7 (12.7)
96 (83.6)
44 (80.0)
43 (78.2)
7 (18.2)
47 (85.4)
17 (30.9)
16 (29.1)
18 (32.7)
(67.3)
(32.7)
(63.6)
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time (PTT), immunoglobulins (IgG, IgA, IgM)
and complement (C, C4), urine levels and the
level of anti-DNA antibodies.
Serum sampling
Venous blood samples for TNF- and TNF
receptor determinations were collected at the
time of clinical assessment into pyrogen-free
tubes, and centrifuged within 20 min after being
allowed to clot at--4C for 1 h at 2000g for
10 min. The serum obtained was divided into
aliquots and stored at -25C until assayed. TNF-
(, IL-6 and sTNF-(x-Rp55 slL-6R were assayed by
specific commercially available, enzyme-linked
(ELISA) assay kits (Quantikine, R&D Systems
Inc., USA) in accordance with the manufac-
turer’s protocols.
In each assay, the appropriate recombinant
human cytokine was used to generate the
standard curve. Sensitivity of the assay for TNF-
was 0.5 pg/ml; for sTNF-(x-Rp55, 7.8 pg/ml;
for IL-6, 0.3 pg/ml. Serum for IL-6R concentra-
tion measurement was diluted 40 times and
its level was measured between 7.8 and
500 pg/ml. The concentrations of cytokines and
soluble receptors in the samples were deter-
mined by interpolation from the standard curve.
Statistical analysis
Differences in parameters between groups were
evaluated with Student’s t-test. The chi-squared
and Fisher’s exact tests were used to analyse
the relationship between cytokines and soluble
receptors serum values and SLE activity.
Internal distribution data were analysed by
Student’s t-test. Correlations were evaluated
using the Spearman rank-sum correlation coeffi-
cient and linear regression calculated with the
least-squares method.
Results are presented with R2 coefficients.
Comparisons and correlations were considered
significant when p < 0.05.
Results
Table 2 shows the results of measurement of
TNF-(, sTNF-ct-Rp55, IL6 and sIL-6R in the
serum of 55 patients with SLE and 16 normal
individuals. In the group of SLE patients 42
were with active and 13 with inactive disease
according to Liang et aL’s scoring system with
our modification. The highest TNF-ct concentra-
tion was in active SLE patients (median
5.1 pg/ml) and the lowest in the healthy control
group (0.6 pg/ml) (p < 0.001). However, a sig-
nificant difference in the serum TNF-(, level was
also noted between active and inactive SLE
patients (p < 0.02). The sTNF-(-Rp55 level was
also higher in SLE patients than in normal
persons (mean values 1695.4 and 749.4, respec-
tively); however, there was no significant differ-
ence between active and inactive SLE.
We found a positive correlation between TNF-
(x concentration and SLE activity score
(R2-- 0.3512, p < 0.05) and sTNF-ct-Rp55 level
and disease activity (R2 =0.2559, p<O.05)
(Fig. 1). There was also a positive correlation
between TNF-(x and sTNF-(x-Rp55 concentra-
tions in the serum of SLE patients (Fig. 2) and a
lack of such correlations in normal controls
(data not shown).
The serum level of IL-6 was higher in SLE
Table 2. Serum levels of TNF-, sTNF-ct-Rp55, IL-6 and slL-6R in patients with SLE and normal controls. Mean values in
pg/ml + SD and range in parentheses
Group All SLE patients Active SLE Inactive SLE Normal control
Cytokines n- 55 n 42 n 13 n 16
and receptors a b c d
Statistical analysis
TNF- 4.5 +/- 7.1 5.1 +/- 7.8 2.7 +/- 3.3 0.6 +/- 0.4 a & d p < 0.001"
b&d p < 0.01"
(0.4-54.0) (0.6 +/- 54.0) (0.4-12.8) (0.1-1.6) c & d p < 0.02*
b&c p<0.02"
sTNF-ct-Rp55 1695.4 +/- 1287.4 1843.2 +/- 1412.3 1217.8 +/- 518.4 749.4 +/- 129.3 a & d p < 0.001"
b&d p<0.001"
(697.0-9458.1) (775.1-9458.1) (697.0-2699.1) (487.0-1002.0) c & d p < 0.01"
b & c p > 0.05
IL-6 15.4 +/- 48.1 19.7 +/- 54.3 1.7 +/- 1.8 1.3 +/- 1.1 a & d p < 0.01"
b&d p<0.01"
(0.1-312.8) (0.6-312.8) (0.1-6.1) (0.3-4.8) c & d p > 0.05
b&c p<0.02"
slL-6R 972.8 + 326.9 1000.5 +/- 351.9 883.2 +/- 203.2 919.9 +/- 186.2 a & d p > 0.05
b&d p > 0.05
(114.6-2266.2) (114.6-226.2) (524.6-1293.0) (610.6-1305.2) c & d p > 0.05
b & c p > 0.05
Differences statistically significant.
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FIG. 1. Correlations between serum TNF-(z sTNF-(z-Rp55, IL-6 and slL-6R with SLE activity. *Exponential regression.
patients (mean 15.4 pg/ml) than in the control
group (mean 1.3) (p<O.O1). However, we
found no difference in serum IL-6 concentra-
tions in inactive SLE compared with normal
individuals (mean 0.8 and 1.0 respectively,
p > 0.05). The median serum levels of slL-6R
were similar in SLE patients and in the control
group as well as in active and inactive SLE
(p > 0.05) (see Table 2). However, there was a
positive correlation between IL-6 and slL-6R
concentrations and SLE activity (Figs 1 and 2).
We also found a significant positive correlation
between the levels of IL-6 and slL-6R in SLE
patients (R2-- 0.1954, p<O.O01) and lack of
such correlations in the normal group (data not
shown).
We also analysed the relationship between
serum concentrations of TNF-e and IL-6 as well
as sTNF-tx-Rp55 and slL-6R (Fig. 2). We observed
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positive correlations between their parameterg
(R
2 0.7008, p < 0.001 and R2 0.3683, p <
0.001, respectively).
Discussion
The objective of our study was to evaluate the
concentrations of two cytokines, TNF-tx and IL-
6, whose role is inflammatory and immunologic
processes is fairly well known, as well as their
soluble receptors, sTNF<z-Rp55 and IL-6R, in
patients with SLE. In the study, the correlation
between concentrations of these peptides and
the activity of SLE as well as the incidence rate
of particular clinical and laboratory symptoms
of the disease was analysed. We have demon-
strated that the concentration of both TNF-cz
and IL-6 in the serum of SLE patients is higher
than in healthy individuals, and that it displays aTNF-a, IL-6 and their soluble receptors concentrations in SLE
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FIG. 2. Correlations between TNF- and sTNF-cz-Rp55, IL-6 and slL-6R, TNF-cz and IL-6 sTNF--Rp55 and slL-6R serum
concentrations in patients with SLE.
positive correlation with the disease activity, demonstrated a decrease in its production by
These results are consistent with the observa- lectin-stimulated mononuclear cells in SLE pa-
tions of other authors.11-15 However, in contrast tients despite the fact that in these cells the
with our studies, Gordon and Emery did not mRNA is higher for TNF-cz than in healthy
27 observe any correlation between TNF-ct concen- individuals. Moreover, monocytes in SLE pa-
tration and SLE activity,
5 and Metsariune et al. tients can spontaneously secrete TNF- in in
did not find IL-6 concentrations to be higher in vitro culture, with immunologic complexes
controls. The being a strong stimulator of its production by SLE patients than in healthy
I6
above differences may arise due to a different these cells.
28 In SLE, a higher TNF-ct concentra-
sensitivity and specificity of the methods ap- tion was also found in the disease affected
plied to assay cytokines (ELISA and bioassay), tissues compared with healthy tissues. It should
and to the number of patients under investiga- also be added that excessive TNF-ct production
tion. may be conditioned genetically. It may be
It seems justified to assume that both TNF-ct associated with the presence of TNF-tx gene,
and IL-6 play a significant role in the pathogen- and this presence can in consequence condition
esis of SLE. In vitro studies show a disturbed the development of autoimmune diseases, in-
production of TNF-ct in SLE. Malave et al. cluding SLE. The above observations may ac-
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count for a higher TNF-c concentration in the
serum of patients with an active form of SLE, as
well as point to a significant role of this
cytokine in the pathogenesis of the disease.
In SLE, anomalies were also observed in the
production process of IL-6 and the response of
target cells to its activity. Lymphocytes T and B,
as well as monocytes of SLE patients produce
IL-6 in greater quantities than their equivalents
in healthy individuals; this intensification in the
production may be induced by immunologic
complexes.13 Another observation was that
lymphocytes B obtained from SLE patients were
more sensitive to the effect of IL-6 in compari-
son with lymphocytes from healthy controls;
thus, this cytokine may be for them an auto-
crinic growth factor.29 Of significance may be
the observation that in SLE patients there is no
evidence of subpopulation of cells specifically
inhibiting IL-6 expression, and that the majority
of lymphocytes B exhibit spontaneous expres-
sion of the receptors for this cytokine.
In our studies, the sTNF-x-Rp55 concentra-
tion in serum was higher in SLE patients than in
healthy controls and correlated positively with
the activity of the disease, which is in agree-
ment with observations by other authors.19-21,31
However, we did not observe differences in the
sIL-6R concentration between SLE patients and
healthy controls, although the concentration of
this cytokine corrrelated positively with the
disease activity.
The studies conducted demonstrate that
sTNF<z-Rp55, along with TNF<z and IL-6, can be
regarded as a marker of SLE activity, whereas
sIL-6 cannot serve as such. Another marker of
the disease activity is soluble receptor IL-2 (slL-
2R, CD25), the concentration of which, when
monitored, can warn of an exacerbation in the
course of SLE.32 Soluble receptors for TNF-cz,
apart from sIL-2R, neopterins, and intracellular
adhesive molecule 1 (IL AM-I), are considered
the best markers of immunologic activity.
17
Determination of the receptors investigated
even has a certain advantage over TNF-x con-
centration measurements, considering that this
cytokine is quickly eliminated from the circula-
tion and can be thus difficult or impossible to
determine by some methods, especially with
bioassays. However, in our study we used the
ELISA method by which it is possible to
determine the fraction of TNF-x that is asso-
ciated with soluble receptors.33 The biological
and pathophysiological role of soluble receptors
for cytokines is as yet little known. If they are
present in serum at a high concentration, they
can inhibit the activity of cytokines.9 Such effect
is observed, for instance, for TNF soluble
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receptors. On the other hand, however, these
receptors can increase TNF-c activitY by stabiliz-
ing its trimetric structure and preventing its
dissociation into inactive monomers.9a7
It is not fully explained yet if the increase in
sTNF--R concentration, observed in our SLE
patients, is sufficient to alter the biological
activity of TNF<z. In individuals exposed to the
endotoxin activity, such effect can be then
achieved at the sTNF-c-R concentration of
5 ng/ml, which value is considerably higher
than in our patients.34 At lower concentrations,
sTNF-x-Rs function as carriers for their ligand
and protect it from proteolysis, constituting a
reservoir of active or potentially active cy-
tokine.35 It has been demonstrated that both
TNF-z and its production stimulating factors
cause at the same time a split-off of soluble
receptors,
17 an evidence of which can be the
positive correlation between TNF-cz and sTNF-
Rs observed in our patients. Therefore, the
concentration of these receptors in serum is
regarded as an indicator of the activity of the
whole TNF- system, and when increased in
the result of the system stimulation, it persists
longer then high TNF-cz concentration.17
Our studies indicate that determination of sIL-
6R concentration, as opposed to sTNF-cz-Rs, is
of less importance in SLE. The concentration of
the former receptor did not significantly differ
in SLE patients and in healthy controls. We have
demonstrated, though, a positive correlation
between the concentration of slLo6R and of IL-6,
as well as between slL-6R concentration and
disease activity. The results obtained are difficult
to interpret since in pathological conditions
characterized by high IL-6R concentration high
slL-6R concentration was also observed.9’36 The
pathophysiological role of sIL-6R has not yet
been fully determined. Nevertheless, IL-6 is
known to bind in physiological conditions with
the chain of this receptor, and the complex
formed binds them with the endothelial chain fl
(gpl30) of the cellular receptor, and only then
transduction of the signal in the cell occurs.37
In in vitro studies on myeloma cell lines it has
been demonstrated that sensitivity of these cells
on IL-5 activity in the presence of sIL-6R in-
creases ten-fold.38
We have shown that the concentration of
TNF-z, IL-6 and sTNF<z-Rp55 was higher in SLE
patients than in healthy individuals, and that
these peptides correlate positively with the
activity of the disease. Although sIL-6R concen-
tration in SLE patients did not significantly
differ, the level of this receptor indicated a
positive correlation with the disease activity
and IL-6 concentrations.TNF-a, IL-6 and their soluble receptors concentrations in SLE
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